发明名称 Quantifying Met Protein for Cancer Treatment
摘要 Methods are provided for treating a gastric cancer patient. A specific Met fragment peptide is precisely quantitated by SRM-mass spectrometry directly in gastric tumor cells collected from gastric tumor tissue that was obtained from the cancer patient and compared to a reference level. If the Met peptide is below the reference level a second therapeutic regimen is used to treat the patient whereas if the Met peptide is above the reference level then a first therapeutic regimen combining, for example, the second regimen with one or more Met inhibitor therapeutic agents may be used to treat the patient.
申请公布号 US2017097354(A1) 申请公布日期 2017.04.06
申请号 US201615276686 申请日期 2016.09.26
申请人 Expression Pathology, Inc. 发明人 CATENACCI Daniel;HEMBROUGH Todd;CECCHI Fabiola;LIAO Wei-Li
分类号 G01N33/574 主分类号 G01N33/574
代理机构 代理人
主权项 1. A method of treating a patient suffering from gastric cancer comprising: (a) detecting and quantitating a specified Met fragment peptide in a protein digest prepared from a tumor sample obtained from the patient and calculating the level of the Met peptide in said sample by selected reaction monitoring using mass spectrometry, (b) comparing the level of said Met fragment peptide to a reference level, and (c) treating said patient with a first therapeutic regimen if the level of said Met fragment peptide level is above said reference level or treating said patient with a second therapeutic regime if the Met fragment peptide level is below the reference level.
地址 Rockville MD US